What is the purpose of LAPaL?
LAPaL aims to facilitate partnerships in the long-acting therapeutics space. It does this by improving access to health interventions. LAPaL is a collaborative database, with the expectation researchers will add technologies and compounds.
This resource covers a wide array of therapeutic areas where long-acting technology is relevant. There is a particular focus on global health:
- HIV
- malaria
- hepatitis
- tuberculosis
- respiratory infections
- mental health disorders
- diabetes
- cancers.
How does LAPaL support research and development?
Facilitating research and development is the primary objective of LAPaL. It provides a unified platform to access and analyse data on emerging long-acting drugs and related technologies. Users are expected include medical professionals, scientists and scientific writers.
It is a centralised repository of verified, open-access information on the pharmacological properties, and intellectual property status, of a curated collection of long-acting therapeutics and their potential applications.
LAPaL contains carefully curated information on:
- the main characteristics of drugs and drug technologies
- an overview of their intellectual property
- clinical trials landscape
- their global regulatory approval status.
What are the benefits of LAPaL?
For medical and scientific professionals
LAPaL is citable. It's a centralised long-acting pharmacological platform for scientific publications, presentations, and abstracts.
For clinical researchers and data analysts
LAPaL provides information about ongoing long-acting therapeutics clinical trials worldwide. Users will be up to date on the progress of long-acting therapeutics in development.
For public and patient involvement professionals
LAPaL provides a wide range of long-acting drugs in critical and chronic illnesses. These illnesses include HIV, Malaria, TB, and cancer. It is an invaluable tool for public and patient involvement (PPI) groups worldwide.
Where can I use it?
LAPaL's comprehensive features are available to explore here. They include:
- In-depth statistical analyses:
Gain insights into drug development trends based on route of administration and therapeutic areas - Global clinical trial data:
Discover registered clinical trials for specific compounds and technologies - Global regulatory landscapes:
Understand the global regulatory approval status for drugs and technologies in development.
Funding
The Medicines Patent Pool launched LAPaL in 2021, with support from global health agency Unitaid. At that time, the focus was on drug delivery technologies.
LAPaL redeveloped to its current from in 2024. This work was a partnership with the Centre of Excellence for Long-acting Therapeutics (CELT) and John Hopkins University’s Long-Acting/Extended-Release Antiretroviral Research Resource Program (LEAP), a National Institute of Health (NIH) funded program.
